Cyclophosphamide (Cytoxan)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 05:46, 20 May 2019 by PeterYang (talk | contribs) (updated links)
Jump to navigation Jump to search

General information

Class/mechanism: Alkylating agent; transformed primarily in the liver to active metabolites which alkylate and crosslink DNA.[1][2]
Route: IV, PO
Extravasation: irritant or neutral, depending on reference; n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 11/16/1959: initial FDA approval

Also known as

  • Code names: Asta B 518, B-518, WR-138719
  • Generic names: CP monohydrate, CPM, cyclophosphamid monohydrate, cyclophosphamide monohydrate
  • Brand names:
Synonyms
Alkyloxan Biodoxan Carloxan Ciclofosfamida Ciclokebir Cicloxal Clafen Claphene
Cyclam Cycloblastin Cycloblastine CYCLO-cell Cycloferon Cyclomide Cyclophar Cyclophospham
Cyclophosphamid Cyclophosphane Cyclostin Cyclostine Cyclotox Cycloxan Cycram Cydoxan
Cyklofosfamid Cyphos Cytophosphan Cytoxan Cytoxan Lyophilized Endoxan Endoxan-N Endoxana
Enduxan Formitex Fosfaseron Genoxal Genuxal Hidrofosmin Ledoxan Ledoxina
Mitoxan Neophos Neosar Oncomide Oncophos Procytox Revimmune Sendoxan
Siklofos Syklofosfamid Tymtran Zuviphos Zycram Zytoxan

References